Articles by Victoria Socha
Daratumumab cuts risk of progression or death by 51% in high-risk smoldering myeloma vs monitoring, AQUILA trial shows.
Thirty-three percent of RRMM patients remain progression free ≥5 years after cilta-cel in CARTITUDE-1.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.